Frank Verwiel
Member Board of Directors @Bavarian Nordic
Signup · Get unlimited contacts
WORK HISTORY
Member Board of Directors @Bavarian Nordic
Copenhagen, DK
Member of Finance Risk Audit and of Nomination Compensation Committees
EDUCATION
INSEAD
MBA
Erasmus University Rotterdam
M.D. (Medical Doctor)
Harvard Business School
PPL, Business Administration and Management, General
SKILLS
ABOUT FRANK VERWIEL
Frank Verwiel M.D. is currently Chairperson of the Board of Directors of Intellia Therapeutics Inc.(NASDAQ: NTLA). He is the chair Nomination Corporate Governance committee as well as a member of the Audit committee of Intellia Therapeutics Inc. He is a member of the Board of directors and Compensation Committee of Capsida Inc, a privately held gene-therapy company. He is member of the Board of Directors and Audit as well as Science committees of Bavarian Nordic (NASDAQ: BAVA).Dr. Verwiel was a member of the Board of Directors of InterMune (NASDAQ: ITMN) until its acquisition by Roche (2014). He was a member of the Board of Directors and Audit committee as well as chairman of the Compensation committee of AveXis Inc.(NASDAQ: AVXS) until its acquisition by Novartis (2018). He was a member of the Board of Directors and Audit committee as well as chairman of the Compensation committee of Achillion Inc.(NASDAQ: ACHN) until it was acquired by Alexion Inc.(2020). He also served as the Chairperson of the Board of Directors of ObsEva (NASDAQ: OBSV). Dr. Verwiel was a member of the Board of Directors and the Health Section Governing Board of BIO (Biotechnology Innovation Organization).Dr. Verwiel was President, CEO and Board member of Aptalis Pharma Inc.(previously known as Axcan Pharma Inc.(NASDAQ: AXCA)) from 2005 until 2014. Dr. Verwiel initiated and led the LBO that resulted in Aptalis to be acquired by TPG Capital. In 2011 Axcan bought the pharmaceutical technology company Eurand. The combined entity was renamed Aptalis Pharma Inc. In 2014 Forest Laboratories Inc. acquired Aptalis Pharma Inc. Previously Dr. Verwiel was with Merck & Co. Inc. in various international senior management positions including Vice President, Hypertension, Worldwide Human Health Marketing. Dr. Verwiel was also Managing Director of Merck\'s Dutch subsidiary and manufacturing operations. During his tenure with Servier Laboratories he was amongst others responsible for Servier\'s Western European operations. Dr. Verwiel holds a Medical Doctor (M.D.) degree from Erasmus University, Rotterdam, the Netherlands and an MBA from INSEAD, Fontainebleau, France.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.